Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocug ...

Overwatch 2 mid-Season 20 update patch notes, Assault return and more

The return of a beloved game mode, hero changes and a brand new Mythic - there's lots to enjoy in the latest Overwatch 2 ...

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...
evo

Used Alpinas – four tuned BMW Bahnstormers from the end of an era

The B3 and D3 have been around in their most recent generation since 2020 but such is the rarity of these cars, they’ve not ...
Business.com on MSN

How do workers’ compensation rates work?

Workers' compensation rates are affected by several factors. Learn what workers' compensation covers, and how to calculate rates and meet requirements.

Targeting epigenetic modifiers and splicing regulators together may offer new acute myeloid leukemia treatment paths

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...